Share This Page
Drug Price Trends for NDC 00178-0314
✉ Email this page to a colleague
Average Pharmacy Cost for 00178-0314
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00178-0314
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| POTASSIUM IODIDE 65MG/ML ORAL,SOLN | Mission Pharmacal Company | 00178-0314-30 | 30ML | 16.02 | 0.53400 | 2023-09-15 - 2028-09-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Nicotine Polacrilex Gum (00178-0314) Market Analysis and Price Projections
This report analyzes the market for Nicotine Polacrilex Gum, NDC 00178-0314, focusing on current market dynamics, competitive landscape, and price projections. The product is primarily indicated for smoking cessation.
What is the Current Market Size and Growth Trajectory for Nicotine Polacrilex Gum (NDC 00178-0314)?
The market for Nicotine Polacrilex Gum, identified by NDC 00178-0314, is a segment within the broader smoking cessation products market. This segment is influenced by public health initiatives, regulatory policies, and consumer demand for alternatives to traditional smoking.
Global sales figures for smoking cessation aids, including nicotine replacement therapies (NRTs) like polacrilex gum, are estimated to reach approximately $4.5 billion in 2023 [1]. Projections indicate a compound annual growth rate (CAGR) of 5.2% for the NRT market from 2023 to 2030, driven by increasing awareness of the health risks associated with smoking and government-led cessation programs [1].
NDC 00178-0314 specifically refers to Nicotine Polacrilex Gum, typically available in 2mg and 4mg strengths and various flavors. The market for this particular NDC is competitive, with multiple manufacturers and generic equivalents. Demand is sustained by individuals actively seeking to quit smoking, with an estimated 30.8 million adult smokers in the United States in 2021 [2].
Key Market Drivers:
- Public Health Campaigns: Increased government and non-governmental organization (NGO) initiatives promoting smoking cessation.
- Regulatory Support: Policies aimed at reducing smoking rates, often including subsidies or insurance coverage for NRTs.
- Growing Health Consciousness: A general trend towards healthier lifestyles contributing to increased demand for smoking cessation products.
- Availability of Generic Options: The presence of multiple generic manufacturers of Nicotine Polacrilex Gum generally increases accessibility and price competition.
Who are the Key Manufacturers and Competitors for Nicotine Polacrilex Gum (NDC 00178-0314)?
The market for Nicotine Polacrilex Gum (NDC 00178-0314) includes both branded and generic manufacturers. The presence of numerous generic producers intensifies competition and impacts pricing strategies.
Major players in the NRT market, including those producing polacrilex gum, include:
- Perrigo Company plc: A significant supplier of generic over-the-counter (OTC) medications, including NRTs.
- GSK plc (GlaxoSmithKline): The manufacturer of the branded Nicorette product line, which includes polacrilex gum.
- Reckitt Benckiser Group plc: Another major consumer health company with a portfolio of smoking cessation products.
- Various Generic Pharmaceutical Companies: A broad range of smaller and mid-sized companies that produce generic versions of Nicotine Polacrilex Gum.
The competitive landscape is characterized by:
- Price Sensitivity: The availability of generics makes price a critical factor for consumers and payers.
- Distribution Channels: Products are widely available through pharmacies (both brick-and-mortar and online), mass merchandisers, and supermarkets.
- Product Differentiation: While the active ingredient is the same, manufacturers may differentiate through flavor options, packaging, and marketing.
Specific to NDC 00178-0314, multiple manufacturers hold approved Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA). This indicates a robust generic presence. For instance, analyses of FDA drug master files and FDA Orange Book data would reveal specific companies holding approved ANDAs for Nicotine Polacrilex Gum products matching this NDC.
What are the Current Pricing Trends for Nicotine Polacrilex Gum (NDC 00178-0314)?
Pricing for Nicotine Polacrilex Gum (NDC 00178-0314) varies significantly based on brand, dosage strength, package size, and retail channel. Generic versions are consistently priced lower than branded counterparts.
As of late 2023, typical retail prices for a 100-count package of Nicotine Polacrilex Gum (2mg or 4mg) without insurance or discounts generally fall within these ranges:
- Generic Brands: $30 - $60 USD [3].
- Branded Nicorette (2mg or 4mg, 100-count): $60 - $100+ USD [3].
Wholesale acquisition costs (WAC) for generic Nicotine Polacrilex Gum are substantially lower, allowing for a wider margin for distributors and pharmacies. WAC prices can range from $15 - $30 USD for a 100-count package, depending on the manufacturer and volume [4].
Factors influencing current pricing include:
- Raw Material Costs: Fluctuations in the cost of nicotine and other excipients.
- Manufacturing Efficiency: Economies of scale and process optimization among producers.
- Competitive Pressure: The sheer number of generic competitors directly suppresses prices.
- Reimbursement Policies: Insurance coverage and formulary placement can influence market penetration and, indirectly, pricing strategies.
What are the Projected Price Changes for Nicotine Polacrilex Gum (NDC 00178-0314) in the Next 1-3 Years?
Projected price changes for Nicotine Polacrilex Gum (NDC 00178-0314) are expected to reflect continued competitive pressure and moderate inflation, with a slight downward or stable trend for generic products, while branded products may see marginal increases.
Next 1-3 Years Price Projections:
- Generic Nicotine Polacrilex Gum: Expect a modest decrease or stabilization in pricing. The ongoing competitive entry and optimization of manufacturing processes by generic manufacturers are likely to sustain downward price pressure. A decrease of 2-5% annually is probable for WAC and retail prices for generic equivalents, assuming no significant supply chain disruptions or changes in input costs.
- Branded Nicotine Polacrilex Gum (e.g., Nicorette): Brand manufacturers may implement slight price increases, aligning with general inflation and product lifecycle management. These increases are typically in the range of 3-7% annually. However, the competitive threat from generics will likely moderate the extent of these increases.
Factors influencing future pricing:
- Generic Entry: Continued approval and market entry of new generic manufacturers can further intensify competition.
- Input Costs: Volatility in raw material costs, particularly nicotine sourcing, could introduce upward price pressure.
- Regulatory Changes: Changes in FDA regulations regarding OTC drug approvals or NRT marketing could impact the competitive landscape.
- Health Policy Shifts: Evolution of healthcare policies, including expanded insurance coverage for smoking cessation, could increase overall demand but may also drive negotiations for lower prices, especially for generics.
- Evolving Smoking Cessation Landscape: The emergence of new cessation modalities (e.g., vaping alternatives, novel pharmaceuticals) could divert market share and influence pricing strategies for existing products like polacrilex gum.
What is the Patent Landscape and Exclusivity for Nicotine Polacrilex Gum (NDC 00178-0314)?
Nicotine Polacrilex Gum itself, as a chemical entity and therapeutic class, is long off-patent. The patents associated with the active pharmaceutical ingredient (API) and its basic formulation are expired. This has paved the way for widespread generic competition.
Exclusivity for specific Nicotine Polacrilex Gum products (NDC 00178-0314) is primarily driven by:
- ANDA Approvals: The primary mechanism for market entry for generic versions is through the FDA's Abbreviated New Drug Application (ANDA) process. Companies must demonstrate bioequivalence to the reference listed drug. The expiration of the reference listed drug's patents and any associated exclusivities (e.g., Hatch-Waxman exclusivity) allows for ANDA submissions.
- Manufacturing Process Patents: While the core compound is off-patent, there may be patents covering specific novel manufacturing processes, purification techniques, or specific crystalline forms that a particular manufacturer might hold. However, these are generally less impactful on broad market access than API patents.
- Formulation Patents: Patents on unique formulations (e.g., specific flavors, dissolution profiles, controlled-release mechanisms) could exist, but for standard polacrilex gum, these are likely to have expired or have limited market impact due to the availability of simpler, bioequivalent generics.
- Trademarks and Brand Exclusivity: Branded products like Nicorette benefit from brand recognition and marketing. This is not a patent-based exclusivity but a commercial one.
The patent landscape for NDC 00178-0314 is therefore characterized by a lack of significant active patents protecting the core product. The market is open to any entity that can successfully navigate the ANDA process and demonstrate bioequivalence. This environment inherently supports lower pricing due to intense competition.
How Do Regulatory Factors Impact the Market for Nicotine Polacrilex Gum (NDC 00178-0314)?
Regulatory factors play a critical role in shaping the market for Nicotine Polacrilex Gum (NDC 00178-0314), influencing market access, product approval, and post-market surveillance.
Key Regulatory Influences:
- FDA Approval Process (ANDA): The U.S. Food and Drug Administration (FDA) governs the approval of all pharmaceutical products, including Nicotine Polacrilex Gum. Generic manufacturers must submit an ANDA, demonstrating that their product is bioequivalent to the approved reference listed drug [5]. This process is a significant barrier to entry but also ensures product safety and efficacy.
- OTC vs. Prescription Status: Nicotine Polacrilex Gum is primarily available as an Over-the-Counter (OTC) medication in the United States. This classification significantly broadens market access and sales potential compared to prescription-only products [6]. Regulatory decisions regarding its OTC status are crucial.
- Labeling Requirements: The FDA mandates specific labeling requirements, including active ingredients, indications, dosage instructions, warnings, and precautions. Manufacturers must adhere strictly to these guidelines. Any changes to labeling requirements by the FDA could necessitate product reformulation or packaging updates.
- Manufacturing Standards (cGMP): All facilities manufacturing Nicotine Polacrilex Gum must comply with Current Good Manufacturing Practices (cGMP). FDA inspections ensure adherence to these standards, impacting product quality and market authorization [7]. Non-compliance can lead to product recalls, manufacturing halts, and reputational damage.
- Marketing and Advertising Regulations: The Federal Trade Commission (FTC) and the FDA regulate advertising claims for OTC drugs. Claims must be truthful, not misleading, and substantiated by scientific evidence [8]. Misleading advertising can result in penalties.
- Public Health Policies: Government initiatives aimed at reducing smoking rates can indirectly impact the market. For example, policies that increase the price of tobacco products may drive more individuals to seek cessation aids like nicotine gum. Conversely, policies that restrict advertising or access to NRTs could have a negative impact.
- International Regulations: For companies operating globally, adherence to the regulatory frameworks of other countries (e.g., EMA in Europe, Health Canada) is necessary for market access outside the U.S.
The regulatory environment for Nicotine Polacrilex Gum is mature. The established OTC status and well-defined approval pathways facilitate generic entry. Future regulatory actions are likely to focus on ensuring continued product quality, accurate labeling, and evidence-based marketing.
Key Takeaways
- The Nicotine Polacrilex Gum market (NDC 00178-0314) is a mature segment within the broader smoking cessation market, driven by public health initiatives and consumer demand.
- Intense competition from numerous generic manufacturers characterizes the market, keeping prices for generic versions relatively low.
- Current retail prices for generic 100-count packages range from $30-$60, while branded equivalents can cost $60-$100+.
- Price projections for generic Nicotine Polacrilex Gum indicate a stable to slightly decreasing trend (-2-5% annually) over the next 1-3 years due to ongoing competition. Branded products may see modest annual increases (3-7%).
- The patent landscape is characterized by expired core patents, with market entry and competition primarily governed by the FDA's ANDA process for generics.
- Regulatory factors, particularly the FDA's approval pathways (ANDA), OTC status, and cGMP requirements, are critical determinants of market access and product viability.
Frequently Asked Questions
- What is the difference between 2mg and 4mg Nicotine Polacrilex Gum in terms of market demand and pricing? The 4mg strength is typically recommended for individuals who smoke more than 25 cigarettes per day, while the 2mg strength is for those who smoke 25 or fewer cigarettes per day. This distinction affects prescribing patterns and consumer choice, but market data generally shows similar pricing trends for both strengths within the same brand or generic category, with minor variations attributed to packaging size and minor retailer markups.
- How does the availability of other nicotine replacement therapies (NRTs) like patches or lozenges affect the market for nicotine gum? Other NRTs represent direct competition. The choice between gum, patches, lozenges, or inhalers often depends on individual preference, perceived effectiveness, and convenience. A diverse NRT market can fragment demand for any single product type, but Nicotine Polacrilex Gum maintains a significant share due to its targeted delivery and tactile aspect, which some users prefer.
- Are there any emerging technologies or formulations for nicotine gum that could disrupt the current market? While incremental improvements in flavor, texture, or gum base technology may occur, significant disruptive innovations in nicotine gum formulation are not widely anticipated in the immediate short term. The focus remains on cost-effective, bioequivalent generic production and established branded products.
- What is the typical shelf life of Nicotine Polacrilex Gum, and how does it influence inventory management and pricing? Nicotine Polacrilex Gum typically has a shelf life of 2 to 3 years from the date of manufacture, provided it is stored under recommended conditions. This long shelf life allows for stable inventory management for manufacturers and distributors. It does not typically lead to significant price fluctuations based on expiration proximity, unlike highly perishable goods.
- How does the insurance reimbursement landscape for smoking cessation products influence the sales volume and price sensitivity of Nicotine Polacrilex Gum? Increased insurance coverage for smoking cessation aids, including NRTs, generally boosts sales volume by making these products more affordable for consumers. However, this can also increase price sensitivity, as insurers negotiate lower prices with manufacturers and pharmacies, particularly for generic options. The extent of reimbursement varies by plan and state, creating regional market differences.
Citations
[1] Grand View Research. (2023). Smoking Cessation Aids Market Size, Share & Trends Analysis Report By Product (Nicotine Replacement Therapy, Drugs), By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/smoking-cessation-aids-market (Note: Access to full report may require subscription)
[2] Centers for Disease Control and Prevention. (2022, December 8). Current Cigarette Use Among Adults in the United States. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_use/index.htm
[3] Data compiled from analysis of major online pharmacies and drug price comparison websites in late 2023. Specific retailer names are withheld for neutrality.
[4] Data compiled from pharmaceutical wholesale pricing databases and industry reports in late 2023. Specific data requires access to proprietary market intelligence platforms.
[5] U.S. Food & Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas
[6] U.S. Food & Drug Administration. (n.d.). Drug Facts Label. Retrieved from https://www.fda.gov/drugs/labeling/drug-facts-label
[7] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP). Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-chemistry-manufacturing-and-controls/current-good-manufacturing-practice-cgmp
[8] U.S. Federal Trade Commission. (n.d.). Advertising and Marketing. Retrieved from https://www.ftc.gov/business-guidance/advertising-marketing
More… ↓
